The 10-second takeaway
For the quarter ended June 30 (Q2), Allergan met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share grew significantly.
Margins expanded across the board.
Allergan reported revenue of $1.49 billion. The 21 analysts polled by S&P Capital IQ expected revenue of $1.50 billion on the same basis. GAAP reported sales were 5.2% higher than the prior-year quarter's $1.42 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.07. The 24 earnings estimates compiled by S&P Capital IQ predicted $1.06 per share. GAAP EPS of $0.96 for Q2 were 22% higher than the prior-year quarter's $0.79 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 86.5%, 30 basis points better than the prior-year quarter. Operating margin was 30.3%, 420 basis points better than the prior-year quarter. Net margin was 19.8%, 240 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $1.43 billion. On the bottom line, the average EPS estimate is $1.05.
Next year's average estimate for revenue is $5.82 billion.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 402 members out of 423 rating the stock outperform, and 21 members rating it underperform. Among 109 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 106 give Allergan a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Allergan is outperform, with an average price target of $101.29.
- Add Allergan to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
We Believe Healthcare's Next Biotech Buyout Target Is…
Which biotech company will be the next buyout target? To answer this question, we turned to three of our healthcare contributors, and this is what they had to say.
Can This Pharma Go From Good to Great?
Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?
Bill Ackman Made His Investors $4.5 Billion Last Year -- Here's How
Bill Ackman's 2014 performance proves that a pricey market still contains undervalued stocks.